Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting

Obesity

Volumn 16, Issue 3, 2008, Pages 623-629

  Schwartz, Susan M ^a,b   Bansal, Vidhu P ^b   Hale, Cecilia ^b   Rossi, Maureen ^a,d   Engle, Janet P ^c  

^a HOFFMANN LA ROCHE INC   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d Drug Safety   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; LACTONE; NON PRESCRIPTION DRUG; TETRAHYDROLIPSTATIN; VITAMIN;

ADULT; ARTICLE; ATTITUDE TO HEALTH; CLINICAL TRIAL; DIET THERAPY; DRUG ADMINISTRATION; DRUG LABELING; EXERCISE; FEMALE; HEALTH BEHAVIOR; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; OBESITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PSYCHOLOGICAL ASPECT; SAFETY; TIME; TREATMENT OUTCOME; UNITED STATES; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; CONSUMER PRODUCT SAFETY; DRUG ADMINISTRATION SCHEDULE; DRUG LABELING; DRUGS, NON-PRESCRIPTION; EXERCISE; FEMALE; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LACTONES; MALE; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VITAMINS; WEIGHT LOSS;

EID: 40149090959     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.96     Document Type: Article

References (17)

1. National Center for Health Statistics (CDC). Prevalence of Overweight and Obesity Among Adults: United States, 2003-2004. . Accessed July 2007.
2. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight (review). Cochrane Library 2005;1-57.
3. FDA approves orlistat for over-the-counter use. FDA News February 7 2007. . Accessed July 2007.
4. Zhi J, Melia AT, Guerciollni R et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82-85.
5. Jacob S, Togerson J. Orlistat Treatment Beneficial in Both Primary Care and Tertiary Settings. Presented at European Congress of Obesity, Athens, Greece, 1-4, June 2005.
6. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal K. Orlistat in the long-term treatment of obesity in the primary care setting. Arch Fam Med 2000;9:160-167.
7. Rossner S, Sjostrom L, Noack R, Meinders E, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000;8:49-61.
8. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235-242.
9. Brass EP. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 2001;345:810-816.
10. Roth H. Harriet Roth's Fat Counter, 2nd revised edn. A Signet Book, Penguin Group, New York, 2000.
11. National Institutes of Health. The Practical Guide. Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH Publication no. 00-4084. Bethesda, Maryland: National Institutes of Health, October 2000.
12. alll website (2007). Accessed July 2007.
13. Guidance for Industry Developing Products for Weight Management Draft Guidance . Accessed August 2007.
14. Wadden TA, Berkowitz RI, Womble LG et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-2120.
15. Package Insert for Xenical. Revised January 2005.
16. Huckleberry Y, Rollins CJ. Prevention of nutritional deficiencies. In: Berardi RR, DeSimone EM, Newton GD et al. (eds.) Handbook of Nonprescription Drugs, 13th edn. Washington, DC: American Pharmaceutical Association, 2000, 491.
17. Zhi J, Melia AT, Twardy-Koss SG, Arara S, Patel IH. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996;36:152-159.